The ins and outs of susceptibility testing for new b-lactam/b-lactamase inhibitor combinations for gram-negative organisms

Loading...
Thumbnail Image

Authors

Dingle, Tanis
Pitout, Johann D.D.

Journal Title

Journal ISSN

Volume Title

Publisher

Journal of Clinical Microbiology

Abstract

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest b-lactam/b-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testing is warranted due to variable activity against certain b-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories.

Description

Keywords

Antimicrobial activity, Antimicrobial susceptibility testing, B-lactamases, B-lactams, Carbapenemase, Antimicrobial resistance (AMR), B-lactam/b-lactamase inhibitors (BL/BLIs)

Sustainable Development Goals

Citation

Dingle, T.C. & Pitout, J. The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms. Journal of Clinical Microbiology 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21.